Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients

Archivum Immunologiae et Therapiae Experimentalis

Volumn 53, Issue 5, 2005, Pages 454-464

  Kraj, Maria ^a   Owczarska, Katarzyna ^a   Sokołowska, Urszula ^a   Centkowski, Piotr ^a   Pogłód, Ryszard ^a   Kruk, Barbara ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Multiple myeloma; Osteolysis; Osteoprotegerin; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADULT; AGED; ARTICLE; BONE DESTRUCTION; BONE MARROW; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; PROTEIN DETERMINATION;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CARRIER PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 30944433586     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Anderson D. M., Maraskovsky E., Billingsley W. L., Dougali W. C., Tometsko M. E., Roux E. R., Teepe M. C., Du Bose R. F., Cosman D. and Galibert L. (1997): A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic - cell function. Nature, 390, 175-179.
2. Bekker P. J., Holloway D., Nakanishi A., Arrighi M., Leese P. T. and Dunstan C. R. (2001): The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone Miner. Res., 16, 348-360.
3. Body J. J., Greipp P., Coleman R. E., Facon T., Geurs F., Fermand J. P., Harousseau J. L., Lipton A., Mariette X., Williams C. D., Nakanishi A., Holloway D., Martin S. W., Dunstan C. R. and Bekker P. J. (2003): A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer, 97, 887-892.
4. Brown J. M., Corey E., Lee Z. D., True L. D., Yun T. J., Tondravi M. and Vessella R. L. (2001): Osteoprotegerin and RANK ligand expression in prostate cancer. Urology, 57, 611-616.
5. Brown J. M., Vessella R. L., Kostenuik P. J., Dunstan C. R., Lange P. H. and Corey E. (2001): Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin. Cancer Res., 7, 2977-2983.
6. Browner W. S., Lui L. Y. and Cummings S. R. (2001): Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab., 86, 631-637.
7. Burgess T. L., Qian Y., Kaufman S., Ring B. D., Van G., Capparelli C., Kelley M., Hsu H., Boyle W. J., Dunstan C. R., Hu S. and Lacey D. L. (1999): The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell. Biol., 145, 527-538.
8. Capparelli C., Kostenuik P. J., Morony S., Starnes C, Weimann B, Van G., Scully S., Qi M., Lacey D. L., Dunstan C. R. (2000): Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcaemia of malignancy. Cancer Res., 60, 783-787.
9. Chen D., Sarikaya N. A., Gunn H., Martin S. W. and Young J. D. (2001): ELISA methodology for detection of modified osteoprotegerin in clinical studies. Clin. Chem., 47, 747-749.
10. Centkowski P., Kraj M. and Kruk B. (2003): Serum osteoprotegerin levels are not reduced in multiple myeloma. Acta Haematol. Pol., 34, 107-114.
11. Corso A., Dovio A., Rusconi C., Sartori M. L., Klersy C., Varettoni M., Mangiacavalli S., Zappasodi P., Ventura M., Angeli A. and Lazzarino M. (2004): Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. Leukemia, 18, 1555-1557.
12. Croucher P. I., Shipman C. M., Lippitt J., Perry M., Asosing K., Hijzen A., Brabbs A. C., van Beek E. J. R., Holen I., Skerry T. M., Dunstan C. R., Russell G. R., van Camp B. and Vanderkerken K. (2001): Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood, 98, 3534-3540.
13. Fahrleitner-Pammer A., Dobnig H., Piswanger-Soelkner C., Bonelli C., Dimai H. P., Leb G. and Obermayer-Pietsch B. (2003): Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien. Klin. Wochenschr., 115, 291-297.
14. Farrugia A. N., Atkins G. J., To L. B., Pan B., Horvath N., Kostakis P., Findlay D. M., Bardy P. and Zannettino A. C. (2003): Receptor activator of nuclear factor κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res., 63, 5438-5445.
15. Fiumara P., Snell V., Li Y., Mukhopadhyay A., Younes M., Gillenwater A. M., Cabanillas F., Aggarwal B. B. and Younes A. (2001): Functional expression of receptor activator of nuclear factor-κB in Hodgkin disease cell lines. Blood, 98, 2784-2790.
16. Giuliani N., Bataille R., Mancini C., Lazzaretti M. and Barille S. (2001): Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood, 98, 3527-3533.
17. Giuliani N., Colla S., Sala R., Moroni M., Lazzaretti M., La Monica S., Bonomini S., Hojden M., Sammarelli G., Barille S., Bataille R. and Rizzoli V. (2002): Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood, 100, 4615-4621.
18. Heider U., Jakob C., Zavrski I., Fleissner C., Eucker J., Possinger K., Hofbauer L. C. and Sezer O. (2003): Expression of receptor activator of nuclear factpr-κB ligand (RANKL) on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin. Cancer Res., 9, 1436-1440.
19. Hofbauer L. C., Neubauer A. and Heufelder A. E. (2001): Receptor activator of nuclear factor-kappa B ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer, 92, 460-470.
20. Hofbauer L. C. and Schoppet M. (2001): Serum measurement of osteoprotegerin - clinical relevance and potential applications. Eur. J. Endocrinol., 145, 681-683.
21. Honore P., Luger N. M., Sabino M. A., Schwei M. J., Rogers S. D., Mach D. B., O'keefe P. F., Ramnaraine M. L., Clohisy D. R. and Mantyh P. W. (2000): Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat. Med., 6, 521-528.
22. Jung K., Lein M., von Hösslin K., Brux B., Schnorr D., Loening S. A. and Sinha P. (2001): Osteoprotegerin in serum as novel marker of bone metastatic spread in prostate cancer. Clin. Chem., 47, 2061-2063.
23. Kong Y. Y., Yoshida H., Sarosi I., Tan H. L., Timms E., Capparelli C., Morony S., Oliviera Dos Santos A. J., Van G., Itie A., Khoo W., Wakeham A., Dustan C. R., Lacey D. L., Mak T. W., Boyle W. J. and Penninger J. M. (1999): OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature, 397, 315-323.
24. Kotake S., Udagawa N., Hakoda M., Mogi M., Yano K., Tsuda E., Takahashi K., Furuya T., Ishiyama S., Kim K. J., Saito S., Nishikawa T., Takahashi N., Togari A., Tomatsu T., Suda T. and Kamatani N. (2001): Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum., 44, 1003-1012.
25. Kraj M. (2003): New concepts in the pathogenesis of myeloma bone disease. Acta Haematol. Pol., 34 (suppl. 1), 105-112.
26. Kraj M., Centkowski P. and Kruk B. (2003): Osteoprotegerin and sRANKL serum levels in multiple myeloma patients. Acta Haematol. Pol., 34 (suppl. 2), 274
27. and Hematol. J., 4 (suppl. 2), 153-154.
28. Kraj M., Sokolowska U., Centkowski P. and Kruk B. (2004): Osteoprotegerin/sRANKL ratio is increased in bone marrow and serum of multiple myeloma patients. Clin. Invest. Med., 27, 168D.
29. Kraj M., Sokotowska U., Kruk B. and Centkowski P. (2005): Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. Haematologica/Hematol. J., 90 (suppl.), 193-194.
30. Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., Willvonseder R. and Austrian Study Group on Normative Values of Bone Metabolism (2003): Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone, 32, 681-686.
31. Kyrtsonis M. C., Vassilakopoulos T. P., Siakantaris M. P., Kokoris S. I., Gribabis D. A., Dimopoulou M. N., Angelopoulou M. K. and Pangalis G. A. (2004): Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur. J. Haematol., 72, 252-258.
32. Lacey D. L., Timms E., Tan H. L., Kelley M. J., Dunstan C. R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y. X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delany J. and Boyle W. J. (1998): Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93, 165-176.
33. Lipton A., Ali S. M., Leitzel K., Chinchilli V., Witters L., Engle L., Holloway D., Bekker P. and Dunstan C. R. (2002): Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8, 2306-2310.
34. Luger N. M., Honore P., Sabino M. A., Schwei M. J., Rogers S. D., Mach D. B., Clohishy D. R. and Mantyh P. W. (2001): Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res., 61, 4038-4047.
35. Michigami T., Ihara-Watanabe M., Yamazaki M. and Ozono K. (2001): Receptor activator of nuclear factor κB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res., 61, 1637-1644.
36. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., Sato Y., Nakagawa N., Yasuda H., Mochizuki S., Gomibuchi T., Yano K., Shima N., Washida N., Tsuda E., Morinaga T., Higashio K. and Ozawa H. (1998): Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/ osteoprotegerin. Biochem Biophys. Res. Commun., 247, 610-615.
37. Moreb J. S., Zucali J. R. and Roberts C. (2003): Monitoring serum and urine osteoprotegerin levels during the treatment of patients with multiple myeloma. Blood, 102, 374b.
38. Morony S., Capparelli C., Sarosi I., Lacey D. L., Dunstan C. R. and Kostenuik P. (2001): Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res., 61, 4432-4436.
39. Nagai M., Kyakumoto S. and Sato N. (2000): Cancer cells responsible for humoral hypercalcemia express mRNA enclosing a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem. Biophys. Res. Commun., 269, 532-536.
40. Nosaka K., Miyamoto T., Sakai T., Mitsuya H., Suda T. and Matsuoka M. (2002): Mechanism of hypercalcemia in adult T-cell leukemia overexpression of receptor activator of nuclear factor κB ligand on adult T-cell leukemia cells. Blood, 99, 634-640.
41. Oyajobi B. O., Anderson D. M., Traianedes K., Williams P. J., Yoneda T. and Mundy G. R. (2001): Therapeutic efficacy of a soluble receptor activator of nuclear factor kappa B - IgG Fc fusion protein in suppressing bone resorption and hypercalcaemia in a model of humoral hypercalcemia of malignancy. Cancer Res., 61, 2572-2578.
42. Pearse R. N., Sordillo E. M., Yaccoby S., Wong B. R., Liau D. F., Colman N., Michaeli J., Epstein J. and Choi Y. (2001): Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. USA, 98, 11581-11586.
43. Politou M., Terpos E., Anagnostopoulos A., Szydlo R., Laffan M., Layton M., Apperley J. F., Dimopoulos M.-A. and Rahemtulla A. (2004): Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br. J. Hematol., 126, 686-689.
44. Roux S., Meignin V., Quillard J., Meduri G., Guiochon-Mantel A., Fermand J. P., Milgrom E. and Mariette X. (2002): RANK (receptor activator of nuclear factor κB) and RANKL expression in multiple myeloma. Br. J. Haematol., 117, 86-92.
45. Seidel C., Hjertner Ø., Abildgaard N., Heickendorff L., Hjorth M., Westin J., Nielsen J. L., Hjorth-Hansen H., Waage A., Sundan A. and Borset M. (2001): Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood, 98, 2269-2271.
46. Sezer O., Heider U., Jakob C., Zavrski I., Eucker J., Possinger K., Sers C. and Krenn V. (2002): Immunocytochemistry reveals RANKL expression of myeloma cells. Blood, 99, 4646-4647.
47. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M. S., Lüthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T., Shimamoto G., De Rose M., Eliott R., Colombero A., Tan H. L., Trial G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T. M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Amgen EST Program and Boyle W. J. (1997): Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89, 309-319.
48. Sordillo E. M. and Pearse R. N. (2003): RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer, 97, 802-812.
49. Standal T., Seidel C., Hjertner Ø., Plesner T., Sanderson R., Waage A., Borset M. and Sundan A. (2002): Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood, 100, 3002-3007.
50. Szulc P., Hofbauer L. C., Heufelder A. E., Roth S. and Delmas P. D. (2001): Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J. Clin. Endocrinol. Metab., 86, 3162-3165.
51. Terpos E., Szydło R., Apperley J. F., Hatjiharissi E., Politou M., Meletis J., Viniou N., Yataganas X., Goldman J. M. and Rahemtulla A. (2003): Soluble receptor activator of nuclear factor κB ligand - osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 102, 1064-1069.
52. Vanderkerken K., De Leenheer E., Shipman C., Asosingh K., Willems A., Van Camp B. and Croucher P. (2004): Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res., 63, 287-289.
53. Wong B. R., Josien R. and Choi Y. (1999): TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J. Leukoc. Biol., 65, 715-724.
54. Yaccoby S., Pearse R. N., Johnson C. L., Barlogie B., Choi Y. and Epstein J. (2002): Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br. J. Haematol., 116, 278-290.
55. Yano K., Tsuda E., Washida N., Kobayashi F., Goto M., Harada A., Ikeda K., Higashio K. and Yamada Y. (1999): Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J. Bone Miner. Res., 14, 518-527.
56. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S. I., Tomoyasu A., Yano K., Goto M., Murakami A., Tsuda E., Morinaga T., Higashio K., Udagawa N., Takahashi N. and Suda T. (1998): Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA, 95, 3597-3602.
57. Zhang J., Dai J., Qi Y., Lin D. L., Smith P., Strayhom C., Mizokami A., Fu Z., Westman J. and Keller E. T. (2001): Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest., 107, 1235-1244.